Featured Research

from universities, journals, and other organizations

New Insight Into How The Immune System Is Finely Balanced In The Livers Of Individuals Chronically Infected With Hepatitis C Virus

Date:
February 24, 2009
Source:
Journal of Clinical Investigation
Summary:
One group of immune cells that help control viral infections are known as T cells. However, it is important to keep these cells under control, as overly vigorous T cell responses can lead to tissue damage, which has potentially serious health consequences.

One group of immune cells that help control viral infections are known as T cells. However, it is important to keep these cells under control, as overly vigorous T cell responses can lead to tissue damage, which has potentially serious health consequences.

Vincenzo Barnaba and colleagues, at Sapienza Universitΰ di Roma, Italy, have now provided new insight into the regulation of cells known as Tregs, which control the balance between an adequate antiviral immune response and suppression of tissue damage, in the livers of patients chronically infected with hepatitis C virus (HCV).

The research is published Feb. 23, 2009, in the Journal of Clinical Investigation.

In an accompanying commentary, Arash Grakoui and colleagues, at Emory University School of Medicine, Atlanta, discuss the clinical importance of these data.

In the study, although Tregs were found to accumulate at sites of infection in the livers of patients chronically infected with HCV, they were substantially fewer in number and proliferated less than effector T cells (the cells that control the viral infection). The level of expression of the protein PD-1 on Tregs inversely correlated with both their ability to proliferate and clinical markers of immune suppression in vivo. In vitro analysis indicated that blocking the interaction between PD-1 and PD-L1 enhanced the proliferation and suppressive function of Tregs from the livers of patients chronically infected with HCV, indicating that PD-L1 negatively regulates Tregs at sites of chronic inflammation.

Further analysis provided evidence of the mechanism underlying this: PD-L1 downregulates STAT-5 phosphorylation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Franceschini et al. PD-L1 negatively regulates CD4 CD25 Foxp3 Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI36604
  2. Grakoui et al. PD-1 tempers Tregs in chronic HCV infection. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI38661

Cite This Page:

Journal of Clinical Investigation. "New Insight Into How The Immune System Is Finely Balanced In The Livers Of Individuals Chronically Infected With Hepatitis C Virus." ScienceDaily. ScienceDaily, 24 February 2009. <www.sciencedaily.com/releases/2009/02/090224004435.htm>.
Journal of Clinical Investigation. (2009, February 24). New Insight Into How The Immune System Is Finely Balanced In The Livers Of Individuals Chronically Infected With Hepatitis C Virus. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/02/090224004435.htm
Journal of Clinical Investigation. "New Insight Into How The Immune System Is Finely Balanced In The Livers Of Individuals Chronically Infected With Hepatitis C Virus." ScienceDaily. www.sciencedaily.com/releases/2009/02/090224004435.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins